Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma

Xenograft Lines, Michelle J. Clarke, Evan A. Mulligan, Patrick T. Grogan, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Nicola J. Curtin, Zhenkun Lou, Paul A. Decker, Wenting Wu, E. Ruth Plummer, Jann N Sarkaria

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888. Using two primary glioblastoma xenografts, the efficacy of ABT-888 combined with radiotherapy and/or temozolomide was evaluated. Treatment with ABT-888 combined with temozolomide resulted in significant survival prolongation (GBM12: 55.1%, P = 0.005; GBM22: 54.4%, P = 0.043). ABT-888 had no effect with radiotherapy alone but significantly enhanced survival in GBM12 when combined with concurrent radiotherapy/ temozolomide. With multicycle therapy, ABT-888 further extended the survival benefit of temozolomide in the inherently sensitive GBM12 and GBM22 xenograft lines. However, after in vivo selection for temozolomide resistance, the derivative GBM12TMZ and GBM22TMZ lines were no longer sensitized by ABT-888 in combination with temozolomide, and a similar lack of efficacy was observed in two other temozolomide-resistant tumor lines. Thus, the sensitizing effects of ABT-888 were limited to tumor lines that have not been previously exposed to temozolomide, and these results suggest that patients with newly diagnosed glioblastoma may be more likely to respond to combined temozolomide/poly(ADP-ribose) polymerase inhibitor therapy than patients with recurrent disease.

Original languageEnglish (US)
Pages (from-to)407-414
Number of pages8
JournalMolecular Cancer Therapeutics
Volume8
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

temozolomide
Glioblastoma
Radiotherapy
Heterografts
Survival
veliparib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma. / Lines, Xenograft; Clarke, Michelle J.; Mulligan, Evan A.; Grogan, Patrick T.; Mladek, Ann C.; Carlson, Brett L.; Schroeder, Mark A.; Curtin, Nicola J.; Lou, Zhenkun; Decker, Paul A.; Wu, Wenting; Plummer, E. Ruth; Sarkaria, Jann N.

In: Molecular Cancer Therapeutics, Vol. 8, No. 2, 01.02.2009, p. 407-414.

Research output: Contribution to journalArticle

Lines, X, Clarke, MJ, Mulligan, EA, Grogan, PT, Mladek, AC, Carlson, BL, Schroeder, MA, Curtin, NJ, Lou, Z, Decker, PA, Wu, W, Plummer, ER & Sarkaria, JN 2009, 'Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma', Molecular Cancer Therapeutics, vol. 8, no. 2, pp. 407-414. https://doi.org/10.1158/1535-7163.MCT-08-0854
Lines, Xenograft ; Clarke, Michelle J. ; Mulligan, Evan A. ; Grogan, Patrick T. ; Mladek, Ann C. ; Carlson, Brett L. ; Schroeder, Mark A. ; Curtin, Nicola J. ; Lou, Zhenkun ; Decker, Paul A. ; Wu, Wenting ; Plummer, E. Ruth ; Sarkaria, Jann N. / Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 2. pp. 407-414.
@article{d4862809102a429a8ade8a5d8e2c3c14,
title = "Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma",
abstract = "Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888. Using two primary glioblastoma xenografts, the efficacy of ABT-888 combined with radiotherapy and/or temozolomide was evaluated. Treatment with ABT-888 combined with temozolomide resulted in significant survival prolongation (GBM12: 55.1{\%}, P = 0.005; GBM22: 54.4{\%}, P = 0.043). ABT-888 had no effect with radiotherapy alone but significantly enhanced survival in GBM12 when combined with concurrent radiotherapy/ temozolomide. With multicycle therapy, ABT-888 further extended the survival benefit of temozolomide in the inherently sensitive GBM12 and GBM22 xenograft lines. However, after in vivo selection for temozolomide resistance, the derivative GBM12TMZ and GBM22TMZ lines were no longer sensitized by ABT-888 in combination with temozolomide, and a similar lack of efficacy was observed in two other temozolomide-resistant tumor lines. Thus, the sensitizing effects of ABT-888 were limited to tumor lines that have not been previously exposed to temozolomide, and these results suggest that patients with newly diagnosed glioblastoma may be more likely to respond to combined temozolomide/poly(ADP-ribose) polymerase inhibitor therapy than patients with recurrent disease.",
author = "Xenograft Lines and Clarke, {Michelle J.} and Mulligan, {Evan A.} and Grogan, {Patrick T.} and Mladek, {Ann C.} and Carlson, {Brett L.} and Schroeder, {Mark A.} and Curtin, {Nicola J.} and Zhenkun Lou and Decker, {Paul A.} and Wenting Wu and Plummer, {E. Ruth} and Sarkaria, {Jann N}",
year = "2009",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-08-0854",
language = "English (US)",
volume = "8",
pages = "407--414",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma

AU - Lines, Xenograft

AU - Clarke, Michelle J.

AU - Mulligan, Evan A.

AU - Grogan, Patrick T.

AU - Mladek, Ann C.

AU - Carlson, Brett L.

AU - Schroeder, Mark A.

AU - Curtin, Nicola J.

AU - Lou, Zhenkun

AU - Decker, Paul A.

AU - Wu, Wenting

AU - Plummer, E. Ruth

AU - Sarkaria, Jann N

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888. Using two primary glioblastoma xenografts, the efficacy of ABT-888 combined with radiotherapy and/or temozolomide was evaluated. Treatment with ABT-888 combined with temozolomide resulted in significant survival prolongation (GBM12: 55.1%, P = 0.005; GBM22: 54.4%, P = 0.043). ABT-888 had no effect with radiotherapy alone but significantly enhanced survival in GBM12 when combined with concurrent radiotherapy/ temozolomide. With multicycle therapy, ABT-888 further extended the survival benefit of temozolomide in the inherently sensitive GBM12 and GBM22 xenograft lines. However, after in vivo selection for temozolomide resistance, the derivative GBM12TMZ and GBM22TMZ lines were no longer sensitized by ABT-888 in combination with temozolomide, and a similar lack of efficacy was observed in two other temozolomide-resistant tumor lines. Thus, the sensitizing effects of ABT-888 were limited to tumor lines that have not been previously exposed to temozolomide, and these results suggest that patients with newly diagnosed glioblastoma may be more likely to respond to combined temozolomide/poly(ADP-ribose) polymerase inhibitor therapy than patients with recurrent disease.

AB - Resistance to temozolomide and radiotherapy is a major problem for patients with glioblastoma but may be overcome using the poly(ADP-ribose) polymerase inhibitor ABT-888. Using two primary glioblastoma xenografts, the efficacy of ABT-888 combined with radiotherapy and/or temozolomide was evaluated. Treatment with ABT-888 combined with temozolomide resulted in significant survival prolongation (GBM12: 55.1%, P = 0.005; GBM22: 54.4%, P = 0.043). ABT-888 had no effect with radiotherapy alone but significantly enhanced survival in GBM12 when combined with concurrent radiotherapy/ temozolomide. With multicycle therapy, ABT-888 further extended the survival benefit of temozolomide in the inherently sensitive GBM12 and GBM22 xenograft lines. However, after in vivo selection for temozolomide resistance, the derivative GBM12TMZ and GBM22TMZ lines were no longer sensitized by ABT-888 in combination with temozolomide, and a similar lack of efficacy was observed in two other temozolomide-resistant tumor lines. Thus, the sensitizing effects of ABT-888 were limited to tumor lines that have not been previously exposed to temozolomide, and these results suggest that patients with newly diagnosed glioblastoma may be more likely to respond to combined temozolomide/poly(ADP-ribose) polymerase inhibitor therapy than patients with recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=60849125726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849125726&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0854

DO - 10.1158/1535-7163.MCT-08-0854

M3 - Article

C2 - 19174557

AN - SCOPUS:60849125726

VL - 8

SP - 407

EP - 414

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -